Projecting future complications of chronic hepatitis C in the United States.

Liver fibrosis. J Clin Invest (2005) 17.27

Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol (2007) 5.77

Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest (2009) 3.80

The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med (2011) 3.80

Treating viral hepatitis C: efficacy, side effects, and complications. Gut (2006) 3.71

Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology (2010) 2.64

Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol (2012) 2.24

Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Aliment Pharmacol Ther (2014) 2.18

Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Aliment Pharmacol Ther (2013) 2.15

Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg (2007) 2.12

Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78

Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med (2016) 1.77

The epidemiology of hepatitis C infection in the United States. J Gastroenterol (2007) 1.71

Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg (2010) 1.68

Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci U S A (2010) 1.67

HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health (2009) 1.62

The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004. Can J Gastroenterol (2008) 1.46

Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology (2009) 1.40

Advanced MRI methods for assessment of chronic liver disease. AJR Am J Roentgenol (2009) 1.39

Use of administrative claims data for identifying patients with cirrhosis. J Clin Gastroenterol (2013) 1.39

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat (2013) 1.37

Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets. J Virol (2006) 1.33

Abdominal magnetic resonance elastography. Top Magn Reson Imaging (2009) 1.26

The metabolomic window into hepatobiliary disease. J Hepatol (2013) 1.24

Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent) (2008) 1.20

Genetics of IL28B and HCV--response to infection and treatment. Nat Rev Gastroenterol Hepatol (2012) 1.20

Decreased aquaporin expression leads to increased resistance to apoptosis in hepatocellular carcinoma. Cancer Lett (2006) 1.19

Current and future disease progression of the chronic HCV population in the United States. PLoS One (2013) 1.17

Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C. Hepatology (2011) 1.13

Regulation of CXCL-8 (interleukin-8) induction by double-stranded RNA signaling pathways during hepatitis C virus infection. J Virol (2006) 1.12

Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest (2013) 1.12

National estimates of healthcare utilization by individuals with hepatitis C virus infection in the United States. Clin Infect Dis (2014) 1.10

The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infect Dis (2012) 1.10

Consilience in sarcopenia of cirrhosis. J Cachexia Sarcopenia Muscle (2012) 1.08

Liver T1ρ MRI measurement in healthy human subjects at 3 T: a preliminary study with a two-dimensional fast-field echo sequence. Br J Radiol (2012) 1.06

MR T1ρ as an imaging biomarker for monitoring liver injury progression and regression: an experimental study in rats with carbon tetrachloride intoxication. Eur Radiol (2012) 1.05

Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (2014) 1.05

Hepatitis C virus induces oxidative stress, DNA damage and modulates the DNA repair enzyme NEIL1. J Gastroenterol Hepatol (2010) 1.03

Interleukin (IL)-17/IL-22-producing T cells enriched within the liver of patients with chronic hepatitis C viral (HCV) infection. Dig Dis Sci (2011) 1.02

Utilization and antiviral therapy in patients with chronic hepatitis C: analysis of ambulatory care visits in the US. Dig Dis Sci (2010) 0.99

Methamphetamine enhances Hepatitis C virus replication in human hepatocytes. J Viral Hepat (2008) 0.97

Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer. Clin Cancer Res (2013) 0.96

Critical role of hypoxia and A2A adenosine receptors in liver tissue-protecting physiological anti-inflammatory pathway. Mol Med (2008) 0.96

Natural killer cells: multifaceted players with key roles in hepatitis C immunity. Immunol Rev (2013) 0.95

Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma. J Transl Med (2009) 0.95

Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma. Free Radic Biol Med (2014) 0.94

Matrix metalloproteinase gene delivery for liver fibrosis. Pharm Res (2007) 0.94

Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis (2013) 0.93

Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transpl (2012) 0.91

Chutes and ladders in hepatitis C nucleoside drug development. Antiviral Res (2013) 0.90

The prevalence of hepatitis C virus infection in Texas: implications for future health care. Proc (Bayl Univ Med Cent) (2005) 0.89

Bioconjugation of oligonucleotides for treating liver fibrosis. Oligonucleotides (2007) 0.88

Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol (2015) 0.87

Elevated CD4+/CD25+ T cell frequency and function during acute hepatitis C presage chronic evolution. Gut (2006) 0.87

Flow cytometry assay of myeloid dendritic cells (mDCs) in peripheral blood during acute hepatitis C: possible pathogenetic mechanisms. World J Gastroenterol (2006) 0.87

Hepatitis C viral kinetics: the past, present, and future. Clin Liver Dis (2013) 0.87

The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence. J Transplant (2014) 0.86

Risk factors for the development of depression in patients with hepatitis C taking interferon-α. Neuropsychiatr Dis Treat (2011) 0.86

Natural killer cell functional dichotomy: a feature of chronic viral hepatitis? Front Immunol (2012) 0.85

Estimating HCV prevalence at the state level: a call to increase and strengthen current surveillance systems. Am J Public Health (2013) 0.85

Seroprevalence of HCV and its co-infection with HBV and HIV among liver disease patients of South Tamil Nadu. World J Hepatol (2010) 0.84

Knowledge of hepatitis C virus screening in long-term pediatric cancer survivors: a report from the Childhood Cancer Survivor Study. Cancer (2010) 0.83

Modeling viral evolutionary dynamics after telaprevir-based treatment. PLoS Comput Biol (2014) 0.83

Targeted venous occlusion using pulsed high-intensity focused ultrasound. IEEE Trans Biomed Eng (2009) 0.83

Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges. Virulence (2015) 0.82

Introduction of an automated system for the diagnosis and quantification of hepatitis B and hepatitis C viruses. Open Virol J (2012) 0.82

The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists. Dig Dis Sci (2011) 0.82

Lack of health insurance limits the benefits of hepatitis C virus screening: insights from the National Health and Nutrition Examination Hepatitis C follow-up study. Am J Gastroenterol (2015) 0.82

Trends in the prevalence of thrombocytopenia among individuals infected with hepatitis C virus in the United States, 1999-2008. BMC Res Notes (2012) 0.82

Current and Future Burden of Chronic Nonmalignant Liver Disease. Clin Gastroenterol Hepatol (2015) 0.81

Inactivated ORF virus shows antifibrotic activity and inhibits human hepatitis B virus (HBV) and hepatitis C virus (HCV) replication in preclinical models. PLoS One (2013) 0.81

The economic burden of advanced liver disease among patients with hepatitis C virus: a large state Medicaid perspective. BMC Health Serv Res (2012) 0.80

Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg (2006) 0.80

Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. Value Health (2016) 0.80

Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol (2016) 0.80

Rising costs and hospital admissions for hepatocellular carcinoma in Portugal (1993-2005). World J Gastroenterol (2007) 0.79

Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition. World J Gastroenterol (2008) 0.79

Patients' willingness to accept the risks and benefits of new treatments for chronic hepatitis C virus infection. Patient (2012) 0.79

Acrolein, a ubiquitous pollutant and lipid hydroperoxide product, inhibits antiviral activity of interferon-alpha: relevance to hepatitis C. Free Radic Biol Med (2009) 0.79

Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C. Hepatology (2015) 0.79

Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more. Dig Dis Sci (2010) 0.79

Recombinant interferon-Beta-1alpha plus ribavirin for the treatment of chronic HCV infection: a prospective, randomized, comparative pilot study. Gut Liver (2009) 0.79

Undiagnosed hepatitis C on the general medicine and trauma services of two urban hospitals. J Infect (2009) 0.79

Hepatitis C Virus Sensing by Human Trophoblasts Induces Innate Immune Responses and Recruitment of Maternal NK Cells: Potential Implications for Limiting Vertical Transmission. J Immunol (2015) 0.79

Optimizing the dose and duration of therapy for chronic hepatitis C. Gut Liver (2009) 0.78

Novel alpha interferon (IFN-alpha) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-alpha2b therapy in a subgenomic replicon system. Antimicrob Agents Chemother (2006) 0.78

Practice patterns in screening for varices: an American survey. Dig Liver Dis (2009) 0.78

Natural history of major complications in hepatitis C virus-related cirrhosis evaluated by per-rectal portal scintigraphy. World J Gastroenterol (2005) 0.78

None of the six SNPs of IL28B could predict treatment responses in genotype 2 chronic HCV infected patients by propensity score matching analysis. PLoS One (2012) 0.78

Development of a flow cytometry live cell assay for the screening of inhibitors of hepatitis C virus (HCV) replication. Open Virol J (2012) 0.78

Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States. Medicine (Baltimore) (2016) 0.78

Hepatitis C virus replication and potential targets for direct-acting agents. Therap Adv Gastroenterol (2010) 0.77

Management of HCV infection and liver transplantation. Int J Med Sci (2006) 0.77

Estimating the true prevalence of hepatitis C in rhode island. R I Med J (2013) (2014) 0.77

Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort. BMC Gastroenterol (2015) 0.77

Regulation of host innate immunity by hepatitis C virus: crosstalk between hepatocyte and NK/DC. Rev Infect (2010) 0.77

Role of living donor liver transplantation in the treatment of hepatitis C virus infection. Hepat Mon (2011) 0.77

Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia. Wien Klin Wochenschr (2006) 0.76

Characteristics of splenic CD8+ T cell exhaustion in patients with hepatitis C. Clin Exp Immunol (2013) 0.76

Clinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States. Int J Med Sci (2004) 0.76

Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology (2012) 7.15

Prevalence and characteristics of opioid use in the US adult population. Pain (2008) 2.49

Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci (2012) 2.05

Occurrence of colon ischemia in relation to irritable bowel syndrome. Am J Gastroenterol (2004) 1.25

Burden of illness in idiopathic pulmonary fibrosis. J Med Econ (2012) 1.21

Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2009) 1.19

The current status of asthma in Korea. J Korean Med Sci (2006) 1.13

Validation of an internet-based cohort of inflammatory bowel disease (CCFA partners). Inflamm Bowel Dis (2014) 1.03

Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression. J Gastroenterol Hepatol (2005) 1.00

Risk factors for colon ischemia. Am J Gastroenterol (2004) 1.00

Evaluation of clinical outcomes with alvimopan in clinical practice: a national matched-cohort study in patients undergoing bowel resection. Ann Surg (2012) 0.95

International variation in medication prescription rates among elderly patients with inflammatory bowel disease. J Crohns Colitis (2012) 0.94

The prevalence of anxiety symptoms and depressive symptoms in patients with somatic disorders in urban China: a multi-center cross-sectional study. Int J Psychiatry Med (2007) 0.93

Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. Am J Gastroenterol (2003) 0.92

Impact of alvimopan (entereg) on hospital costs after bowel resection: results from a large inpatient database. P T (2011) 0.90

Coronary heart disease outcomes among chronic opioid and cyclooxygenase-2 users compared with a general population cohort. Pharmacoepidemiol Drug Saf (2011) 0.89

Factors associated with response to lamivudine: Retrospective study in a tertiary care clinic serving patients with chronic hepatitis B. J Gastroenterol Hepatol (2005) 0.89

Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation. Pharmacoepidemiol Drug Saf (2006) 0.88

Demographic, behavioral, and knowledge factors associated with herpes simplex virus type 2 infection among men whose current female partner has genital herpes. Sex Transm Dis (2005) 0.86

The effect of zanamivir treatment on influenza complications: a retrospective cohort study. Clin Ther (2002) 0.86

Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. Arthritis Res Ther (2014) 0.86

Perceptions of patients with inflammatory bowel diseases on biobanking. Inflamm Bowel Dis (2015) 0.86

Chronic hepatitis B: a long-term retrospective cohort study of disease progression in Shanghai, China. J Gastroenterol Hepatol (2003) 0.85

Prevalence of opioid dispensings and concurrent gastrointestinal medications in an elderly population from Ontario, Canada. J Opioid Manag (2008) 0.82

The burden of comedication among patients with inflammatory bowel disease. Inflamm Bowel Dis (2013) 0.81

Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era. J Heart Lung Transplant (2010) 0.80

Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational study. Chest (2015) 0.78

Risk for respiratory events in a cohort of patients receiving inhaled zanamivir: a retrospective study. Clin Ther (2002) 0.77

Collecting Biospecimens From an Internet-Based Prospective Cohort Study of Inflammatory Bowel Disease (CCFA Partners): A Feasibility Study. JMIR Res Protoc (2016) 0.75

Chest radiographs in the evaluation of febrile infants under 3 months of age. Clin Pediatr (Phila) (2002) 0.75

Exploring Methods to Measure the Prevalence of Ménière's Disease in the US Clinformatics™ Database, 2010-2012. Audiol Neurootol (2016) 0.75